Christine Greco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christine Greco has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Donado
Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
3 shared publications - Bridget A. Nestor
Department of Psychology, Endicott College, Beverly, MA, USA; Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, MA, USA; Department of Anesthesia, Harvard Medical School, Boston, MA, USA
2 shared publications - Camila Koike
Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, United States; Department of Anesthesia, Harvard Medical School, Boston, MA, United States
2 shared publications - Jean Carmela Solodiuk
Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
2 shared publications - Joe Kossowsky
Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, MA, United States
2 shared publications - Kimberly Lobo
Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 21
Alcohol use in adolescent chronic pain: Prevalence rates, perceptions of risk, and predictors of use
- 18 September 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 21
Open AccessAlcohol use in adolescent chronic pain: Prevalence rates, perceptions of risk, and predictors of use
- Open Access
Buprenorphine for Children and Adolescents with Sickle Cell Disease: A Scoping Review
Background and Objective: Sickle cell disease (SCD) is an inherited blood disorder associated with recurrent painful crises. Sickle cell pain crises are a significant source of distress for patients and contribute substantially to hospital utilization among SCD populations. Many children with SCD also experience chronic pain, which is often multifactorial in nature. The management of both acute and chronic pain in SCD commonly relies on opioid medications. Acute and chronic use of opioids is associated with health risks and potential complications, which has raised interest in alternatives. Buprenorphine is a partial μ-receptor agonist with strong affinity that confers pain relief and may have an improved side-effect profile. While there is emerging evidence for its use in adult patients, the data is less developed in pediatrics. Methods: A scoping review was designed in accordance with PRISMA guidelines to systematically explore the literature on buprenorphine use in pain management for children with sickle cell disease (SCD). Results: This review shows that the published literature in this area is of low quality and extremely limited, and there is a lack of trials specifically designed to address the use of buprenorphine for this patient population. Studies are limited in their generalizability but suggest that buprenorphine may be useful in managing pain in this population. Conclusions: While promising, more data is required both retrospectively and prospectively to understand the utility of buprenorphine. The development of pediatric-specific protocols for transitioning from full µ-receptor agonist opioids to buprenorphine is also needed.
Open AccessBuprenorphine for Children and Adolescents with Sickle Cell Disease: A Scoping Review
Background and Objective: Sickle cell disease (SCD) is an inherited blood disorder associated with recurrent painful crises. Sickle cell pain crises are a significant source of distress for patients and contribute substantially to hospital utilization among SCD populations. Many children with SCD also experience chronic pain, which is often multifactorial in nature. The management of both acute and chronic pain in SCD commonly relies on opioid medications. Acute and chronic use of opioids is associated with health risks and potential complications, which has raised interest in alternatives. Buprenorphine is a partial μ-receptor agonist with strong affinity that confers pain relief and may have an improved side-effect profile. While there is emerging evidence for its use in adult patients, the data is less developed in pediatrics. Methods: A scoping review was designed in accordance with PRISMA guidelines to systematically explore the literature on buprenorphine use in pain management for children with sickle cell disease (SCD). Results: This review shows that the published literature in this area is of low quality and extremely limited, and there is a lack of trials specifically designed to address the use of buprenorphine for this patient population. Studies are limited in their generalizability but suggest that buprenorphine may be useful in managing pain in this population. Conclusions: While promising, more data is required both retrospectively and prospectively to understand the utility of buprenorphine. The development of pediatric-specific protocols for transitioning from full µ-receptor agonist opioids to buprenorphine is also needed.
- Open Access
- 9 March 2026
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 42 (6)
An Interdisciplinary Young Adult Pain Rehabilitation Program
Context: Chronic pain affects 1 in 9 young adults worldwide. Intensive interdisciplinary pain treatment (IIPT) has shown favorable outcomes in improving in pain intensity, mood, school attendance, and social and physical functioning in pediatric studies. However, few IIPT programs are designed for young adults (YAs), a distinctly vulnerable developmental stage. Given this limitation, we sought to study the benefits of applying an IIPT model for YAs with chronic pain and functional impairment. Objectives: This study aimed to (1) describe the design and implementation of our pilot YA-IIPT program and (2) assess outcomes of YA-IIPT on pain experience, psychological and physical functioning, disability, and quality of life, in YAs with chronic pain and functional impairment. Methods: In this observational study, we adapted the pediatric IIPT model for YAs using a biopsychosocial approach to chronic pain treatment. Outcome measures included physical functioning, psychological functioning, disability, quality of life, and pain experience. Paired t tests and repeated-measure ANOVAs were used to compare admission, discharge, 6-week, and 6-month follow-up data. Results: Patients showed clinically and statistically significant improvements across the majority of physical and psychological functioning, disability, quality of life, and pain experience measures between admission and discharge ( P <0.01). Most improvements were maintained at 6-week and 6-month follow-ups. Discussion: On average, participants in our YA-IIPT program demonstrated clinically and statistically significant improvements in most areas of functioning, quality of life, and pain experience that were maintained after discharge. Further research is needed on YA pain treatment and whether outcomes after YA-IIPT are sustained long-term.
- 9 March 2026
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 42 (6)
Open AccessAn Interdisciplinary Young Adult Pain Rehabilitation Program
Context: Chronic pain affects 1 in 9 young adults worldwide. Intensive interdisciplinary pain treatment (IIPT) has shown favorable outcomes in improving in pain intensity, mood, school attendance, and social and physical functioning in pediatric studies. However, few IIPT programs are designed for young adults (YAs), a distinctly vulnerable developmental stage. Given this limitation, we sought to study the benefits of applying an IIPT model for YAs with chronic pain and functional impairment. Objectives: This study aimed to (1) describe the design and implementation of our pilot YA-IIPT program and (2) assess outcomes of YA-IIPT on pain experience, psychological and physical functioning, disability, and quality of life, in YAs with chronic pain and functional impairment. Methods: In this observational study, we adapted the pediatric IIPT model for YAs using a biopsychosocial approach to chronic pain treatment. Outcome measures included physical functioning, psychological functioning, disability, quality of life, and pain experience. Paired t tests and repeated-measure ANOVAs were used to compare admission, discharge, 6-week, and 6-month follow-up data. Results: Patients showed clinically and statistically significant improvements across the majority of physical and psychological functioning, disability, quality of life, and pain experience measures between admission and discharge ( P <0.01). Most improvements were maintained at 6-week and 6-month follow-ups. Discussion: On average, participants in our YA-IIPT program demonstrated clinically and statistically significant improvements in most areas of functioning, quality of life, and pain experience that were maintained after discharge. Further research is needed on YA pain treatment and whether outcomes after YA-IIPT are sustained long-term.
- 24 January 2026
- Published by Elsevier in The Journal of Pain
- Vol. 41, 106200
Assessing relationships between cognition, sleep, and mental health in pediatric patients with chronic pain
- 24 January 2026
- Published by Elsevier in The Journal of Pain
- Vol. 41, 106200
Assessing relationships between cognition, sleep, and mental health in pediatric patients with chronic pain
- Open Access
Short-Duration Systemic Lidocaine for the Management of Refractory Chronic Pain in Pediatrics
Objectives: Multidisciplinary management of chronic pain benefits many patients, although some continue to experience refractory pain. Administration of lidocaine infusions (LI) to manage certain chronic pain conditions has been reported in adults, but evidence is limited for its utility in managing pediatric chronic pain. We reviewed LIs for refractory pain in children to (1) describe the patient population that received LI and (2) evaluate the response to LI. Methods: With IRB approval, a retrospective review of patients receiving LI for refractory pain between 2016 and 2021 was conducted at Boston Children’s Hospital. Demographic, medical, pain, sleep, and school function information was collected through self-report and from the electronic medical record. Longitudinal outcomes for a subset of these patients were analyzed using the Chronic Pain Repository database. Results: During the study period, 3959 patients presented for management of chronic pain. Among this population, 184 (5%) patients aged 22 years or younger ultimately received LI as part of their pain management. A total of 350 LIs were administered and were well tolerated. During approximately 42% of the infusions, patients experienced an immediate statistically significant decrease in pain scores. Among the patients with follow-up data, pain improvement was not sustained. Discussion: LI for the treatment of chronic pain appears safe and may be useful for managing refractory pain in pediatrics. Although approximately half of the patients who received LI reported an immediate positive response, the small follow-up sample did not show a continued response. Study limitations preclude demonstrating long-term efficacy of LI; therefore, a prospective study is critical.
Open AccessShort-Duration Systemic Lidocaine for the Management of Refractory Chronic Pain in Pediatrics
Objectives: Multidisciplinary management of chronic pain benefits many patients, although some continue to experience refractory pain. Administration of lidocaine infusions (LI) to manage certain chronic pain conditions has been reported in adults, but evidence is limited for its utility in managing pediatric chronic pain. We reviewed LIs for refractory pain in children to (1) describe the patient population that received LI and (2) evaluate the response to LI. Methods: With IRB approval, a retrospective review of patients receiving LI for refractory pain between 2016 and 2021 was conducted at Boston Children’s Hospital. Demographic, medical, pain, sleep, and school function information was collected through self-report and from the electronic medical record. Longitudinal outcomes for a subset of these patients were analyzed using the Chronic Pain Repository database. Results: During the study period, 3959 patients presented for management of chronic pain. Among this population, 184 (5%) patients aged 22 years or younger ultimately received LI as part of their pain management. A total of 350 LIs were administered and were well tolerated. During approximately 42% of the infusions, patients experienced an immediate statistically significant decrease in pain scores. Among the patients with follow-up data, pain improvement was not sustained. Discussion: LI for the treatment of chronic pain appears safe and may be useful for managing refractory pain in pediatrics. Although approximately half of the patients who received LI reported an immediate positive response, the small follow-up sample did not show a continued response. Study limitations preclude demonstrating long-term efficacy of LI; therefore, a prospective study is critical.
- 3 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (1) , e67-e76
Development and Preliminary Testing of the Withdrawal Assessment Tool-Alpha 2 Agonist: An Assessment Instrument for Monitoring Iatrogenic Withdrawal Symptoms in Children Receiving an Alpha-2 Agonist
OBJECTIVES: To develop and conduct preliminary testing of the Withdrawal Assessment Tool-Alpha 2 Agonist (WAT-A2A) to monitor dexmedetomidine and clonidine withdrawal symptoms in acutely ill children. DESIGN: Three-phase instrument development study. Phase 1: retrospective chart review of symptoms exhibited by children with documented dexmedetomidine withdrawal; phase 2: WAT-A2A instrument construction based on phase 1 data; and phase 3: prospective testing of the WAT-A2A in children weaning from alpha 2 agonists (A2As). SETTING: Academic free-standing children’s hospital. PATIENTS: Acutely ill children weaning from at least 5 days of dexmedetomidine. Excluded were children concurrently weaning other sedatives. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Phase 1: In 83 of 303 children weaning from at least 5 days of dexmedetomidine who had clinician documentation and were managed for A2A withdrawal, 88% (n = 72) exhibited at least a 20% increase in heart rate (HR), 83% (n = 69) exhibited agitation or change in usual state behavior, 46% (n = 38) exhibited at least a 20% increase in diastolic blood pressure (DBP), and when documented, 56% (27/48) exhibited tremors during their A2A withdrawal episode. Phase 2: The WAT-A2A was constructed, based on phase 1 data, and includes four items: HR, state behavior, DBP, and tremors. Phase 3: The WAT-A2A was tested and performed well in 82 children weaning from A2A. The total WAT-A2A score correlated with clinician subjective assessment of A2A withdrawal (Spearman correlation = 0.5; p < 0.001). Inter-rater agreement, comparing paired ratings of prospectively collected WAT-A2A data, indicated moderate inter-rater reliability. CONCLUSIONS: Acutely ill children receiving sedation with an A2A for more than 5 days may develop physiologic dependence, requiring gradual dosing reductions. While further psychometric testing is advised, the WAT-A2A provides an objective instrument to help clinicians quantify dexmedetomidine withdrawal symptoms in acutely ill children may facilitate A2A weaning and limit unnecessary variation in practice.
- 3 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (1) , e67-e76
Development and Preliminary Testing of the Withdrawal Assessment Tool-Alpha 2 Agonist: An Assessment Instrument for Monitoring Iatrogenic Withdrawal Symptoms in Children Receiving an Alpha-2 Agonist
OBJECTIVES: To develop and conduct preliminary testing of the Withdrawal Assessment Tool-Alpha 2 Agonist (WAT-A2A) to monitor dexmedetomidine and clonidine withdrawal symptoms in acutely ill children. DESIGN: Three-phase instrument development study. Phase 1: retrospective chart review of symptoms exhibited by children with documented dexmedetomidine withdrawal; phase 2: WAT-A2A instrument construction based on phase 1 data; and phase 3: prospective testing of the WAT-A2A in children weaning from alpha 2 agonists (A2As). SETTING: Academic free-standing children’s hospital. PATIENTS: Acutely ill children weaning from at least 5 days of dexmedetomidine. Excluded were children concurrently weaning other sedatives. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Phase 1: In 83 of 303 children weaning from at least 5 days of dexmedetomidine who had clinician documentation and were managed for A2A withdrawal, 88% (n = 72) exhibited at least a 20% increase in heart rate (HR), 83% (n = 69) exhibited agitation or change in usual state behavior, 46% (n = 38) exhibited at least a 20% increase in diastolic blood pressure (DBP), and when documented, 56% (27/48) exhibited tremors during their A2A withdrawal episode. Phase 2: The WAT-A2A was constructed, based on phase 1 data, and includes four items: HR, state behavior, DBP, and tremors. Phase 3: The WAT-A2A was tested and performed well in 82 children weaning from A2A. The total WAT-A2A score correlated with clinician subjective assessment of A2A withdrawal (Spearman correlation = 0.5; p < 0.001). Inter-rater agreement, comparing paired ratings of prospectively collected WAT-A2A data, indicated moderate inter-rater reliability. CONCLUSIONS: Acutely ill children receiving sedation with an A2A for more than 5 days may develop physiologic dependence, requiring gradual dosing reductions. While further psychometric testing is advised, the WAT-A2A provides an objective instrument to help clinicians quantify dexmedetomidine withdrawal symptoms in acutely ill children may facilitate A2A weaning and limit unnecessary variation in practice.
- 11 January 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (5) , e409-e415
Patient Controlled Analgesia for Vaso-Occlusive Episodes in Children: A Retrospective Study
- 11 January 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (5) , e409-e415
Patient Controlled Analgesia for Vaso-Occlusive Episodes in Children: A Retrospective Study
- 22 February 2020
- Published by Springer Nature
- p. 79-94
Neonatal and Pediatric Pharmacology